Pontus Nobréus appointed as Business Development Director

Biovica announces the appointment of Pontus Nobréus as Business Development Director, effective end of May 2018. Mr Nobréus has over 20 years’ experience working within the global sales, commercial and business development roles.  Most recently, he was Global Sales Manager at Euro Diagnostica.

2018-11-21T11:43:00+00:00 May 3rd, 2018 08:00|News|

Nomination Committee for Biovica for the 2018 Annual General Meeting

Uppsala, Sweden, 2018-04-23, In accordance with the decision of the Annual General Meeting of Biovica International AB on August 31st, 2017, the Nomination Committee shall consist of three members, representing the two shareholders with the highest number of shares willing to be included in the Nomination Committee, and the Chairman of the Board. The Nomination Committee then elects the chairman.

2018-11-21T11:43:00+00:00 April 24th, 2018 10:08|News|

Biovica receives order worth 100 000 USD

Uppsala, Sweden 2018-03-20  Biovica has received an order for the company's DiviTum® product from a global diagnostic and contract research company (CRO company). DiviTum will be used during the development of a new targeted drug against cancer to study the effectiveness of the treatment.

2018-11-21T11:43:01+00:00 March 20th, 2018 08:00|Press Release|

New Operations Manager at Biovica

Uppsala, December 5, 2017. Biovica has appointed Adam Germunder as new Operations Manager. Adams responsibilities include to build and secure the company’s production capabilities and ensure that they meet regulatory requirements in preparation for the commercialization of DiviTum®.

2018-11-21T11:43:01+00:00 December 5th, 2017 08:30|Press Release|

Researchers at Washington University report: DiviTum® can evaluate the biologic activity of blockbuster breast cancer drug after two weeks

Uppsala, Sweden, November 23, 2017. Results of a study from Washington University, St Louis, demonstrate that the DiviTum® can evaluate the biologic activity of Pfizer’s breast cancer drug palbociclib (Ibrance®) in just two weeks are published in the latest edition of the scientific journal Breast Cancer Research and Treatment. This shortening of the response evaluation window can improve outcome and increase quality of life for breast cancer patients.

2018-11-21T11:43:01+00:00 November 23rd, 2017 08:00|Press Release|